Marina Garassino (@marinagarassino) ranks #40 among US lung cancer KOLs on X in 2026, by engagement from fellow physicians. 3 physicians shared, quoted or replied to their posts this year. CMS Open Payments lists $92,271 in 2025 general payments. This profile tracks their 2026 rankings and the physicians who amplify them on X.
At a Glance
- Lung Cancer: US #40 · 3 physicians engaged
- Presented at ESMO 2026 in 2026
- CMS Open Payments lists $92,271 in 2025 general payments.
This Month
What Marina Garassino has posted in the last 30 days. Updated November 10, 2026.
No trial posts in the last 30 days.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Lung Cancer | #40 | — | 3 | 4 | Full ranking |
From the Podium, 2025–26
Talks, posters and sessions Marina Garassino presented at SABCS 2025 and 2026 meetings, each confirmed by a public source.
- ESMO 2026 · Proffered paper (2519O)Association of biomarkers with efficacy in the phase 3 KEYNOTE-671 study of perioperative pembrolizumab plus neoadjuvant chemotherapy in early-stage non-small-cell lung cancer
- ESMO 2026 · Session chairThymic tumours state of the art sessionSource: @MMoscvin on X ↗
What Colleagues Are Saying About Marina Garassino
2026 posts by fellow physicians that mention @marinagarassino, quoted word for word.
#ESMO26 The brilliant Dr. @marinagarassino with biomarker analysis from the phase III KEYNOTE 671 study of perioperative pembrolizumab for resectable NSCLC showing association of T-cell inflamed gene expression profile and TMB with efficacy. Benefit across subgroups; inflamed profile associated with better prognosis. #ESMOAmbassadors
🆙 #ESMO26 Proffered Paper: #LCSM Non-Mets NSCLC, others 🔥Association of Biomarkers With Efficacy in the Phase 3 KEYNOTE-671 Study of Perioperative Pembrolizumab Plus Neoadjuvant Chemotherapy in Early-Stage Non–Small-Cell Lung Cancer 🎙️ @marinagarassino 🔢2519O ☑️NCT03425643 🔗 https://t.co/grEfaUchKN @OncoAlert @Larvol @myESMO @IASLC
Another presentation Dr. @marinagarassino from @UCCancerCenter @UChicagoMed with biomarker analysis of KEYNOTE-671 for resectable early stage NSCLC. https://t.co/7urBmqr9iR
A couple of #happy #Wefies 📸 at @IASLC #WCLC26 🇰🇷. Looking forward to the formal start of events tomorrow! See you all bright and early! @ZerAlona @abcduke @g_mountzios @marinagarassino #AaronTan #DaisyMak and many others! https://t.co/ycGCgQwUMR
Industry Payments
CMS Open Payments · 2025 general payments
$92,271 across 67 payments